Invizius key facts
as of Oct 2026- Developer of a complementary-regulating therapy platform designed to mitigate harmful immune responses in extracorporeal medical procedures.
- Invizius is valued at approximately $47.8M as of Oct 2026 (last reported valuation).
- It has raised $18.7M; the latest was Later Stage VC ($13.4M) in Jun 2026.
- Notable investors include Innovate UK, Scottish Enterprise, SyndicateRoom, Mercia Ventures, Meltwind Advisory — 18 tracked in total.
- Status: Privately Held (backing).
Invizius's last reported valuation, Jun 2026. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch Invizius: the Monday email on marks, rounds and moves
Invizius funding rounds
No funding rounds for Invizius are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Invizius
18+Invizius valuation
Invizius's last reported valuation was $47.8 million in Jun 2026. No priced round, secondary trade or fund mark has surfaced since.
Invizius investors
18 investors are on record for Invizius, including Innovate UK, Scottish Enterprise, SyndicateRoom and Mercia Ventures.
About Invizius
Developer of a complementary-regulating therapy platform designed to mitigate harmful immune responses in extracorporeal medical procedures. The company offers a novel priming protein that coats dialysis circuits, suppresses complement activation, and preserves infection control for reducing mortality and morbidity, enabling clinicians treating patients on dialysis and other extracorporeal support to reduce inflammation-related complications and improve patient safety.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2018
- Employees
- 10
- Website
- invizius.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.